This website is intended for a UK audience

So that we can direct you to the most appropriate information about Decapeptyl SR (triptorelin), please choose one of the following options:

I am a healthcare professional in the UK*

*This section of the website is for UK healthcare professionals only and contains promotional content regarding our medicines.

Reporting of adverse events (healthcare professionals in the UK)

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777

I am a patient in the UK who has been prescribed this medicine
I am a member of the general public in the UK

Reporting of side effects (patients and public in the UK)

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine.

TRI-UK-005698 Date of preparation: February 2024

For UK-based Healthcare Professionals only
Search

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard

Adverse events should also be reported to the Ipsen Medical Information Department on +44(0) 1753 627777 or pharmacovigilance.uk-ie@ipsen.com

A link to the prescribing information can be found in the header.

Practical prescribing of Decapeptyl® SR (triptorelin)

Practical information to help you prescribe LHRHa therapy with Decapeptyl® SR. This includes the licenced indications for Decapeptyl® SR in prostate cancer, the triptorelin mechanism of action video, dosing and administration information for the 1 monthly (28 days)-, 3 monthly (12 weeks) and 6 monthly (24 weeks) formulations of Decapeptyl® SR.

Decapeptyl® SR for prostate cancer treatment

Decapeptyl® SR indications in prostate cancer are as follows:1-3

  • Locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration
  • Metastatic prostate cancer
  • High-risk localised or locally advanced prostate cancer, as a neoadjuvant treatment prior to radiotherapy
  • Locally advanced prostate cancer at high risk of disease progression, as an adjuvant treatment to radical prostatectomy

Decapeptyl® SR mechanism of action

Play

Decapeptyl® SR contains triptorelin which is a synthetic analogue of luteinising hormone-releasing hormone (LHRH), which is also known as gonadotrophin-releasing hormone (GnRH).1-3

Triptorelin acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses.1-3

After administration of triptorelin there is an initial and transient increase in circulating levels of luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone in males and oestradiol in females.1-3

Continuous and long-term administration of triptorelin, however, results in decreased LH and FSH secretion and suppression of testicular and ovarian steroidogenesis.1-3

Decapeptyl® SR leads to testosterone suppression in prostate cancer patients

Sustained release formulation

Triptorelin is contained within microspheres that are designed for sustained release.4

Microspheres are spherical particles that consist of a continuous network of support material or polymer in which the active substance is dispersed.

The different stages of triptorelin microsphere breakdown4

Adapted from Tissier et al 1990

Decapeptyl® SR dosing

Decapeptyl® SR is the only LHRHa with 1-, 3- and 6-monthly dosing options available in the UK.1-3

Decapeptyl® SR releases a steady dose of triptorelin after injection for the dosing period specified. For this reason, select the dosing formulation most appropriate for your patient. Please note two 3-monthly injections given at the same time is not the same as giving one 6-monthly injection. The former would result in double the amount of triptorelin being released over 3 months.6

3 mg

A single intramuscular injection every 28 days

11.25 mg

A single intramuscular injection every 3 months

22.5 mg

A single intramuscular every 6 months (24 weeks)

Decapeptyl® SR administration

Decapeptyl® SR is licenced to be administered by a healthcare professional and should not be administered by a patient or carer.

Decapeptyl® SR preparation and administration video

Play

Step-by-step guide to preparing and administering Decapeptyl® SR

A – Ensure patient is ready

Ensure the patient is ready for injection. Decapeptyl® SR must be administered immediately after reconstitution to avoid the product from precipitating and blocking the injection needle.

Prepare the patient by disinfecting the injection site. Break the neck of the ampoule (ensuring the dot faces you).

Draw up all the solvent into the syringe with Needle 1 (needle without safety device).

Remove the green tab on top of the vial and insert Needle 1 vertically through the bung.

Transfer the solvent into the vial containing the powder.

B – Pull up Needle 1

Pull up Needle 1 above the liquid level.

Do not remove the needle from the vial.

C – Swirl the vial

Swirl the vial from side to side during mixing with the needle above the liquid level but to not invert the vial.

Swirl until a homogenous mixture is obtained.

Check there is no unsuspended powder in the vial (if any powder clumps are present, continue swirling until they disappear).

D – Draw up without inverting vial

Draw up all the suspension without inverting the vial.

A small amount will remain in the vial and should be discarded. An overage is included to allow for this loss.

Remove Needle 1 used for the reconstitution.

Attach the other needle – Needle 2 (needle with safety device) to the syringe tip (screw on tightly). Only grasp the coloured hub to connect the needle.

E – Move safety sheath away from needle

Move the safety sheath away from the needle and towards the syringe barrel.

The safety sheath remains in the position you set.

F – Remove needle protection

Remove the needle protection from the needle.

Prime the needle to remove air from the syringe and inject immediately into the gluteal muscle or other appropriate site for IM injection.*

 

 

G  – After injection, activate the safety system

After injection, activate the safety system using a one- handed technique (ensure the finger is kept behind the tab at all times).

Option 1: push the tab forward with the finger.

Option 2: push the sheath to a flat surface.

In both cases press down with a firm, quick motion until a distinct audible click is heard.

 

H – Check needle is under the lock

Visually confirm that the needle is fully engaged under the lock

Dispose of the needles as per local requirements.

*The choice a clinical decision. Injection is usually into a buttock but other intramuscular injection sites are not excluded

Download the Decapeptyl® SR administration guide

Download now

References

  1. Decapeptyl® SR 3 mg Summary of Product Characteristics. Ipsen Ltd.
  2. Decapeptyl® SR 11.25 mg Summary of Product Characteristics. Ipsen Ltd.
  3. Decapeptyl® SR 22.5 mg Summary of Product Characteristics. Ipsen Ltd.
  4. Tissier B. Drug delivery of peptides. In: Bouchard P, Haour F, Franchimont P, Schatz B, editors. Recent progress on GnRH and gonadal peptides. Elsevier, Paris; 1990. p.159–68.
  5. Bolton EM, Lynch T. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. BJU Int. 2018; 122(3):371–83.
  6. Ipsen Data on File TRI-UK-004598
Close

Contact an Ipsen Representative

Contact us

Expand

Contact

Close

Contact an Ipsen Representative

If you would like to learn more about Decapeptyl® SR (triptorelin) for your practice, please fill in your contact details. One of our team will contact you to discuss your query.
By providing your email address, you agree to receive an email response from Ipsen to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.
Please note that this form is not for reporting of adverse events. Information on how to report an adverse event can be found here.

TRI-UK-004985
Date of prep: June 2023

Back to top